Access

Nature Medicine 14, 469 (1 May 2008) | doi:10.1038/nm0508-469;

Return to the basics might breathe life into HIV vaccine pipeline

Roxanne Khamsi

As the financial world grapples with major market corrections, the HIV research community faces its own reality check. The scientific reassessment comes after disappointing results from a candidate HIV vaccine developed by Merck caused the company to halt human trials of the potential vaccine last September.

$rb.Type.Code